Phio Pharmaceuticals (PHIO) Competitors $2.11 -0.01 (-0.47%) Closing price 04:00 PM EasternExtended Trading$2.10 -0.01 (-0.47%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. ATNM, AADI, INMB, IPSC, ADAP, VNRX, ESLA, KPTI, LTRN, and MRSNShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), INmune Bio (INMB), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), VolitionRx (VNRX), Estrella Immunopharma (ESLA), Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Its Competitors Actinium Pharmaceuticals Aadi Bioscience INmune Bio Century Therapeutics Adaptimmune Therapeutics VolitionRx Estrella Immunopharma Karyopharm Therapeutics Lantern Pharma Mersana Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings. Which has more volatility & risk, ATNM or PHIO? Actinium Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Does the media refer more to ATNM or PHIO? In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for Actinium Pharmaceuticals and 0 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.95 beat Actinium Pharmaceuticals' score of -0.33 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Actinium Pharmaceuticals Neutral Phio Pharmaceuticals Positive Do analysts prefer ATNM or PHIO? Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 208.22%. Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 563.51%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, ATNM or PHIO? Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.11Phio PharmaceuticalsN/AN/A-$7.15M-$3.25-0.65 Do insiders and institutionals believe in ATNM or PHIO? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ATNM or PHIO more profitable? Phio Pharmaceuticals' return on equity of -88.75% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Phio Pharmaceuticals N/A -88.75%-77.98% SummaryPhio Pharmaceuticals beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.09M$2.63B$6.09B$10.54BDividend YieldN/A57.78%5.73%4.78%P/E Ratio-0.6522.9984.6327.10Price / SalesN/A761.84606.05131.34Price / CashN/A175.9337.8662.13Price / Book3.065.3212.246.58Net Income-$7.15M$33.06M$3.32B$276.75M7 Day Performance-4.09%-0.81%0.76%0.91%1 Month PerformanceN/A9.20%8.03%4.18%1 Year Performance-20.38%-3.82%71.13%35.42% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals1.9976 of 5 stars$2.11-0.5%$14.00+563.5%-34.8%$12.09MN/A-0.6510ATNMActinium Pharmaceuticals2.1922 of 5 stars$1.61+8.1%$4.50+179.5%-13.1%$50.23MN/A-1.1630AADIAadi BioscienceN/A$2.02-6.9%N/A-1.9%$49.89M$25.07M-0.8940Gap UpINMBINmune Bio2.1425 of 5 stars$1.83-1.6%$18.50+910.9%-64.5%$49.45M$10K-0.7410IPSCCentury Therapeutics2.7822 of 5 stars$0.55-3.3%$3.75+581.9%-64.5%$49.13M$6.59M-1.90170ADAPAdaptimmune Therapeutics1.9705 of 5 stars$0.18-2.6%$1.35+650.5%-77.6%$49.01M$178.03M-0.28490Gap DownVNRXVolitionRx2.5983 of 5 stars$0.45-2.5%$3.50+673.1%-39.1%$48.71M$1.32M-1.2680News CoverageGap UpHigh Trading VolumeESLAEstrella Immunopharma2.6753 of 5 stars$1.50+16.3%$16.00+966.7%+87.3%$47.81MN/A-5.77N/AShort Interest ↓Gap DownHigh Trading VolumeKPTIKaryopharm Therapeutics4.1999 of 5 stars$5.62+2.2%$18.20+223.8%-52.6%$47.69M$145.24M-0.39380Analyst RevisionLTRNLantern Pharma1.9179 of 5 stars$4.41+1.6%$25.00+466.9%+23.4%$46.87MN/A-2.4820News CoverageGap DownMRSNMersana Therapeutics4.3022 of 5 stars$9.91+7.3%$56.60+471.1%-80.0%$46.11M$40.50M-0.68150High Trading Volume Related Companies and Tools Related Companies ATNM Competitors AADI Competitors INMB Competitors IPSC Competitors ADAP Competitors VNRX Competitors ESLA Competitors KPTI Competitors LTRN Competitors MRSN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
